ARTICLE | Clinical News
LB1148: Phase II started
September 19, 2016 7:00 AM UTC
Leading BioSciences began the double-blind, placebo-controlled, international Phase II PROFILE trial to evaluate 700 mL oral LB1148 given 8-10 hours before undergoing elective bowel resection in about...